膀胱癌治疗的新进展和新疗法。
New and Emerging Therapies in the Management of Bladder Cancer.
机构信息
Department of Medicine, Division of Oncology, University of North Carolina School of Medicine, Houpt Physician's Office Building, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599, USA.
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
出版信息
F1000Res. 2020 Sep 16;9. doi: 10.12688/f1000research.26841.1. eCollection 2020.
The treatment landscape for bladder cancer has undergone a rapid evolution in the past five years with the approval of seven new agents. New classes of medications have improved outcomes for many patients who previously had limited treatment options, but there is still much to learn about how to optimize patient selection for these agents and the role of combination therapies. The aims of this review are to discuss these newly approved agents for bladder cancer and to feature promising drugs and combinations-including immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates-that are in development.
过去五年，膀胱癌的治疗领域发生了快速变化，有七种新药物获得批准。新类别的药物改善了许多以前治疗选择有限的患者的预后，但仍有许多关于如何优化这些药物的患者选择以及联合治疗的作用的问题需要了解。本文的目的是讨论这些新批准用于膀胱癌的药物，并介绍正在开发的有前途的药物和联合药物，包括免疫检查点抑制剂、靶向治疗和抗体药物偶联物。
Zotero 插件